This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
NextGen Virtual Visits Supports Women Health During COVID-19
by Zacks Equity Research
Capital Women's Care is set to expand NextGen's (NXGN) women's healthcare services during the coronavirus emergency.
Allscripts' (MDRX) Veradigm Partners with PAN Foundation
by Zacks Equity Research
This partnership between Allscripts (MDRX) and PAN Foundation is expected to boost patient outcomes.
Masimo Launches Masimo SafetyNet-Open to Fight Coronavirus
by Zacks Equity Research
Masimo's (MASI) newly-launched SafetyNet-Open has been developed to ensure health and safety during the coronavirus outbreak.
Here's Why You Should Retain Glaukos in Your Portfolio Now
by Zacks Equity Research
Investor confidence is high on Glaukos (GKOS) stock, thanks to solid prospects.
ABIOMED Unveils Digital Platform CAMP PCI for CAD Treatment
by Zacks Equity Research
ABIOMED's (ABMD) new digital platform helps to deliver better patient outcomes for those suffering from CAD.
Here's Why You Should Add HMS Holdings to Your Portfolio Now
by Zacks Equity Research
Investor confidence is high on HMS Holdings (HMSY) stock, thanks to solid prospects.
Can SurModics (SRDX) Run Higher on Rising Earnings Estimates?
by Zacks Equity Research
SurModics (SRDX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Surmodics Gets CE Mark for SurVeil Drug-Coated Balloon
by Zacks Equity Research
Surmodics' (SRDX) receipt of CE Mark for SurVeil DCB should boost the company's Medical Devices segment.
Here's Why You Should Retain LHC Group (LHCG) Stock Now
by Zacks Equity Research
Investor confidence is high in LHC Group (LHCG), thanks to solid prospects
Amedisys (AMED) Broadens Hospice Base With AseraCare Buyout
by Zacks Equity Research
Amedisys (AMED) expects AseraCare business to add greater scale to its existing nationwide network.
Medtronic Alters ECMO Therapy on New FDA Rules for Coronavirus
by Zacks Equity Research
Medtronic (MDT), in response to the FDA's new guidance due to the coronavirus-led health emergency, has made temporary alterations to its cardiopulmonary product indications for use in ECMO therapy.
Tandem Diabetes Rides on Control-IQ Amid Coronavirus Crisis
by Zacks Equity Research
Strong domestic pump sales and international expansion boosts sales of Tandem Diabetes (TNDM).
Here's Why You Should Hold on to Tandem Diabetes Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Tandem Diabetes (TNDM) on robust pump sales and international growth.
HEXO in Focus: Stock Moves 9% Higher
by Zacks Equity Research
HEXO saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
QIAGEN Sales Grow on Coronavirus Solutions Ahead of Selloff
by Zacks Equity Research
QIAGEN (QGEN) ramps up production capacity of solutions currently being used for testing purposes.
Here's Why You Should Add QIAGEN (QGEN) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about QIAGEN (QGEN) on robust segmental and geographical growth.
Thermo Fisher (TMO) Partners With CSL to Expand Pharma Arm
by Zacks Equity Research
Thermo Fisher (TMO), through its alliance with CSL, expands Pharma Services arm to meet the rising demand for biologic therapies.
Quest Diagnostics' Self-Collection Coronavirus Kit Gets EUA
by Zacks Equity Research
This kit by Quest Diagnostics (DGX) is suitable for use in children supervised by an adult.
SurModics (SRDX) Up 1.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
SurModics (SRDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
LabCorp Partners With Medable to Expand Technology Ecosystem
by Zacks Equity Research
LabCorp (LH) expands technology ecosystem to accelerate the adoption of decentralized clinical trials by collaborating with Medable.
Zimmer Biomet Faces Procedure Delays, Long-Term Potential Solid
by Zacks Equity Research
Zimmer Biomet (ZBH) believes COVID-19 to continue to have a significant unfavorable impact on its sales in the near term.
Here's Why You Should Hold on to Chemed (CHE) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Chemed (CHE) on robust segmental growth.
Teleflex (TFX) Rides on UroLift Sales Amid Coronavirus Mayhem
by Zacks Equity Research
NeoTract, the acquired business of Teleflex (TFX), continues to perform impressively.
IDEXX Sees Higher Clinical Visits Despite Coronavirus Crisis
by Zacks Equity Research
IDEXX (IDXX) notes a significant improvement in U.S. clinical visit trends across major regions.
Henry Schein Sales Drop on Coronavirus Woes, Costs Rise
by Zacks Equity Research
Henry Schein (HSIC) registers dismal performance within Dental business on suspension of non-emergency procedures in response to the pandemic.